Heron Therapeutics, Inc. (HRTX) — Analyst outlook / Analyst consensus target is. Based on 19 analyst ratings, the consensus is bullish — 19 Buy.
The consensus price target is $6.67 (low: $5.00, high: $9.00), representing an upside of 597.2% from the current price $0.96.
Analysts estimate Earnings Per Share (EPS) of $-0.13 and revenue of $0.14B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.09 vs est $-0.13 (beat +30.9%). 2025: actual $-0.12 vs est $-0.09 (missed -33.3%). Analyst accuracy: 65%.
HRTX Stock — 12-Month Price Forecast
$6.67
▲ +597.19% Upside
Average Price Target
Based on 19 Wall Street analysts offering 12-month price targets for Heron Therapeutics, Inc., the average price target is $6.67, with a high forecast of $9.00, and a low forecast of $5.00.
The average price target represents a +597.19% change from the last price of $0.96.
Highest Price Target
$9.00
Average Price Target
$6.67
Lowest Price Target
$5.00
HRTX Analyst Ratings
Buy
Based on 19 analysts giving stock ratings to Heron Therapeutics, Inc. in the past 3 months
EPS Estimates — HRTX
65%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.09
vs Est –$0.13
▲ 44.6% off
2025
Actual –$0.12
vs Est –$0.09
▼ 25.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — HRTX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.144B
vs Est $0.141B
▲ 2.4% off
2025
Actual $0.155B
vs Est $0.154B
▲ 0.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
